Literature DB >> 9738026

Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.

M Lozano-Chiu1, V L Paetznick, M A Ghannoum, J H Rex.   

Abstract

Although reliable detection of resistance in vitro is critical to the overall performance of any susceptibility testing method, the recently released National Committee for Clinical Laboratory Standards M27-A methodology for susceptibility testing of yeasts discriminates poorly between resistant and susceptible isolates of Candida spp. We have previously shown that both substitution of antibiotic medium 3 for RPMI 1640 medium in the microdilution variant of the M27-A method and use of the E-test agar diffusion methodology permit detection of amphotericin B-resistant Candida isolates. To determine the relevance of these observations to Cryptococcus neoformans, we have evaluated the performances of both the M27-A and the E-test methodologies with this yeast using three different media (RPMI 1640 medium, antibiotic medium 3, and yeast nitrogen base). As with Candida, we found that only antibiotic medium 3 permitted consistent detection of resistant isolates when testing was performed in broth by the M27-A method. When testing was performed by the E-test agar diffusion method, both RPMI 1640 medium and antibiotic medium 3 agar permitted ready detection of the resistant isolates. Reading of the results after 48 h of incubation was required for testing in broth by the M27-A method, while the MIC could be determined after either 48 or 72 h when the agar diffusion method was used.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738026      PMCID: PMC105070     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Serogroup distribution of Cryptococcus neoformans in patients with AIDS.

Authors:  E J Bottone; I F Salkin; N J Hurd; G P Wormser
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

2.  Serotypes of Cryptococcus neoformans in patients with AIDS.

Authors:  M G Rinaldi; D J Drutz; A Howell; M A Sande; C B Wofsy; W K Hadley
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

3.  The variety of Cryptococcus neoformans in patients with AIDS.

Authors:  R Y Shimizu; D H Howard; M N Clancy
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

Review 4.  Current concepts in cryptococcosis.

Authors:  T F Patterson; V T Andriole
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

5.  Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis.

Authors:  T Joseph-Horne; R S Loeffler; D W Hollomon; S L Kelly
Journal:  J Med Vet Mycol       Date:  1996 Jun-Jul

6.  Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates.

Authors:  A Wanger; K Mills; P W Nelson; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

7.  Susceptibility testing of Cryptococcus neoformans: a microdilution technique.

Authors:  M A Ghannoum; A S Ibrahim; Y Fu; M C Shafiq; J E Edwards; R S Criddle
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

Review 8.  Nosocomial fungal infections. Old problems and new challenges.

Authors:  E Anaissie; G P Bodey
Journal:  Infect Dis Clin North Am       Date:  1989-12       Impact factor: 5.982

9.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; R A Larsen; J Chiu; M A Leal; J Jacobsen; P Rothman; P Robinson; G Gilbert; J A McCutchan; J Tilles
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

10.  Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media.

Authors:  D L Calhoun; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

View more
  28 in total

1.  Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991.

Authors:  M Lozano-Chiu; P W Nelson; V L Paetznick; J H Rex
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

Review 2.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose.

Authors:  J L Rodríguez-Tudela; F Martín-Díez; M Cuenca-Estrella; L Rodero; Y Carpintero; B Gorgojo
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and influence of culture medium.

Authors:  Belkys Fernández-Torres; Isabel Inza; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008.

Authors:  Nelesh P Govender; Jaymati Patel; Marelize van Wyk; Tom M Chiller; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

6.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Relationship between susceptibility of Candida spp. isolates to amphotericin B and death or survival of patients with candidemia episodes.

Authors:  Sydney Hartz Alves; Everton Boff; Patricia Pozzatti; Liliane A Scheid; Erico de Loreto; Loiva T Ottoneli Oliveira; Valério Aquino; Luiz Carlos Severo; Janio Morais Santurio
Journal:  Mycopathologia       Date:  2008-09-26       Impact factor: 2.574

9.  Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species.

Authors:  Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Bianca A Bouman; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

10.  In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.

Authors:  J Chandenier; K D Adou-Bryn; C Douchet; B Sar; M Kombila; D Swinne; M Thérizol-Ferly; Y Buisson; D Richard-Lenoble
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-13       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.